Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment

References

• Fitzmaurice C, Abate D, Barber RM, et al.; Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol. 2019;5(12):1749–1768.
   PubMed Web of Science ®Google Scholar
• DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438–451. doi:10.3322/caac.21583
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341–1352. doi:10.1016/S0140-6736(15)61074-1
   PubMed Web of Science ®Google Scholar
• Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233–247. doi:10.1146/annurev-med-070909-182917
   PubMed Web of Science ®Google Scholar
• Zheng J, Wu J, Wang C, Zhuang S, Chen J, Ye F. Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a systematic review and meta-analysis. PLoS One. 2020;15(6):e0233571. doi:10.1371/journal.pone.0233571
   PubMed Web of Science ®Google Scholar
• Pfizer. A study of palbociclib in addition to standard endocrine treatment in hormone receptor positive Her2 normal patients with residual disease after neoadjuvant chemotherapy and surgery (PENELOPE-B). NLM identifier: NCT01864746. Available from: https://clinicaltrials.gov/ct2/show/NCT01864746. Accessed December 4, 2020.
   Google Scholar
• Eli Lilly and Company. Endocrine therapy with or without abemaciclib (LY2835219) following surgery in participants with breast cancer (monarchE). NLM identifier: NCT03155997. Available from: https://ClinicalTrials.gov/show/NCT03155997. Accessed December 4, 2020.
   Google Scholar
• Novartis Pharmaceuticals. A trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer (NATALEE). NLM identifier: NCT03701334. Available from: https://ClinicalTrials.gov/show/NCT03701334. Accessed December 4, 2020.
   Google Scholar
• Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, Phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425–439. doi:10.1016/S1470-2045(15)00613-0
   PubMed Web of Science ®Google Scholar
• Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–1936. doi:10.1056/NEJMoa1607303
   PubMed Web of Science ®Google Scholar
• Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638–3646. doi:10.1200/JCO.2017.75.6155
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–1748. doi:10.1056/NEJMoa1609709
   PubMed Web of Science ®Google Scholar
• Sledge W, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875–2884. doi:10.1200/JCO.2017.73.7585
   PubMed Web of Science ®Google Scholar
• Thill M, Schmidt M. Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer. Ther Adv Med Oncol. 2018;10:1758835918793326. doi:10.1177/1758835918793326
   Web of Science ®Google Scholar
• Ball S, Swarup S, Sultan A, Thein KZ. Increased risk of cardiac conduction abnormalities with ribociclib in patients with metastatic breast cancer: a combined analysis of phase III randomized controlled trials. Hematol Oncol Stem Cell Ther. 2020:S1658-3876(20)30047-30049. doi:10.1016/j.hemonc.2020.03.001
   Google Scholar
• Loibl S, Turner NC, Ro J, et al. Palbociclib combined with fulvestrant in premenopausal women with advanced breast cancer and prior progression on endocrine therapy: PALOMA-3 results. Oncologist. 2017;22(9):1028–1038. doi:10.1634/theoncologist.2017-0072
   PubMed Web of Science ®Google Scholar
• GoodRx.com [homepage on the internet]. Breast Cancer Medications; 2020. Available from: https://www.goodrx.com/breast-cancer/drugs. Accessed September 20, 2020.
   Google Scholar
• Schaecher KL. A payer’s perspective on CDK4/6 inhibitors. J Hematol Oncol Pharm. 2018. Available from http://jhoponline.com/jhop-supplements?view=article&secid=15250:march-2018-abemaciclib-fda-approval&artid=17419:a-payer-s-perspective-on-cdk4-6-inhibitors. Accessed January 21, 2021.
   Google Scholar
• Guerra RL, Castaneda L, de Albuquerque R, et al. Patient preferences for breast cancer treatment interventions: a systematic review of discrete choice experiments. Patient. 2019;12(6):559–569. doi:10.1007/s40271-019-00375-w
   Google Scholar
• daCosta DiBonaventura M, Copher R, Basurto E, Faria C, Lorenzo R. Patient preferences and treatment adherence among women diagnosed with metastatic breast cancer. Am Health Drug Benefits. 2014;7(7):386–396.
   PubMedGoogle Scholar
• Beusterien K, Grinspan J, Tencer T, Brufsky A, Visovsky C. Patient preferences for chemotherapies used in breast cancer. Int J Womens Health. 2012;4:279–287. doi:10.2147/IJWH.S31331
   Google Scholar
• Maculaitis MC, Liu X, Will O, et al. Oncologist and patient preferences for attributes of CDK4/6 inhibitor regimens for the treatment of advanced/metastatic HR positive/HER2 negative breast cancer: discrete choice experiment and best-worst scaling. Patient Prefer Adherence. 2020;14:2201–2214. doi:10.2147/PPA.S254934
   Web of Science ®Google Scholar
• Bridges JF, Hauber AB, Marshall D, et al. Conjoint analysis applications in health–a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14(4):403–413. doi:10.1016/j.jval.2010.11.013
   PubMed Web of Science ®Google Scholar
• Crivera C, Nelson WW, Schein JR, Witt EA. Attitudes toward anticoagulant treatment among nonvalvular atrial fibrillation patients at high risk of stroke and low risk of bleed. Patient Prefer Adherence. 2016;10:795–805.
   PubMed Web of Science ®Google Scholar
• Hauber BA, Fairchild AO, Johnson FR. Quantifying benefit-risk preferences for medical interventions: an overview of a growing empirical literature. Appl Health Econ Health Policy. 2013;11(4):319–329. doi:10.1007/s40258-013-0028-y
   PubMedGoogle Scholar
• Louviere J, Hensher D, Swait J. Stated Choice Methods: Analysis and Application. Cambridge: Cambridge University Press; 2000.
   Google Scholar
• Johnston S, Martin M, Di Leo A, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019;5(1):5. doi:10.1038/s41523-018-0097-z
   PubMed Web of Science ®Google Scholar
• Dickler MN, Tolaney SM, Rugo HS, et al. MONARCH 1, a Phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR(+)/HER2(-) metastatic breast cancer. Clin Cancer Res. 2017;23(17):5218–5224. doi:10.1158/1078-0432.CCR-17-0754
   PubMed Web of Science ®Google Scholar
• Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373(3):209–219. doi:10.1056/NEJMoa1505270
   PubMed Web of Science ®Google Scholar
• Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005;366(9484):455–462. doi:10.1016/S0140-6736(05)67059-6
   PubMed Web of Science ®Google Scholar
• Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst. 2001;93(9):684–690. doi:10.1093/jnci/93.9.684
   PubMed Web of Science ®Google Scholar
• Chirgwin JH, Giobbie-Hurder A, Coates AS, et al. Treatment adherence and its impact on disease-free survival in the breast international group 1-98 trial of tamoxifen and letrozole, alone and in sequence. J Clin Oncol. 2016;34(21):2452–2459. doi:10.1200/JCO.2015.63.8619
   PubMed Web of Science ®Google Scholar
• Colleoni M, Sun Z, Price KN, et al. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group trials I to V. J Clin Oncol. 2016;34(9):927–935. doi:10.1200/JCO.2015.62.3504
   PubMed Web of Science ®Google Scholar
• Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38(34):3987–3998. doi:10.1200/JCO.20.02514
   PubMed Web of Science ®Google Scholar
• Wouters H, Maatman GA, Van Dijk L, et al. Trade-off preferences regarding adjuvant endocrine therapy among women with estrogen receptor-positive breast cancer. Ann Oncol. 2013;24(9):2324–2329.
   PubMed Web of Science ®Google Scholar
• Lipton NJ, Jesin J, Warner E, et al. Willingness of women with early estrogen receptor-positive breast cancer to take adjuvant CDK4/6 inhibitors. Curr Oncol. 2020;27(3):127–134. doi:10.3747/co.27.6131
   Web of Science ®Google Scholar
• Ritzwoller DP, Fishman PA, Banegas MP, et al. Medical care costs for recurrent versus de novo stage IV cancer by age at diagnosis. Health Serv Res. 2018;53(6):5106–5128. doi:10.1111/1475-6773.13014
   Web of Science ®Google Scholar
• Gast KC, Cathcart-Rake EJ, Norman A, et al. Accuracy of self-reported cancer treatment data in young breast cancer survivors. J Patient Rep Outcomes. 2019;3(1):24. doi:10.1186/s41687-019-0114-5
   Google Scholar
• Kool M, Bastiaannet E, Van de Velde CJH, Marang-van de Mheen PJ. Reliability of self-reported treatment data by patients with breast cancer compared with medical record data. Clin Breast Cancer. 2018;18(3):234–238. doi:10.1016/j.clbc.2017.08.005
   Web of Science ®Google Scholar
• Barisic A, Glendon G, Weerasooriya N, Andrulis IL, Knight JA. Accuracy of self-reported breast cancer information among women from the Ontario site of the breast cancer family Registry. J Cancer Epidemiol. 2012;2012:310804. doi:10.1155/2012/310804
   PubMedGoogle Scholar